A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This study will characterize the effect of PF-04217329, alone and in combination with
latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood
samples will be collected to measure the amount of active metabolite of PF-04217329 in the
plasma following dosing.